Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxDecipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/in Retrospective studies/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/in Oncolytic, Preclinical Research/by MaxPSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial
/in Post-hoc/by MaxNewsletter 34/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with a picture of the Milky Way. August may still be a slow month, but there is always something new to discover. Stay strong and fight on! As usual, we also have a podcast […]
Alpha DaRT: A Promising Frontier in the Treatment of Prostate, Bladder, and Advanced Cancers
/in Clinical Trial, Localized, Metastatic/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025